The treatment of myasthenia gravis. 1948

L R C AGNEW

UI MeSH Term Description Entries
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L R C AGNEW
January 1984, Ugeskrift for laeger,
L R C AGNEW
June 1959, GP,
L R C AGNEW
February 1979, Rational drug therapy,
L R C AGNEW
July 1946, The Medical press,
L R C AGNEW
February 1982, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
L R C AGNEW
March 1961, Medicinski glasnik,
L R C AGNEW
May 2018, Neurologic clinics,
L R C AGNEW
January 1963, Lancet (London, England),
L R C AGNEW
May 1936, British medical journal,
L R C AGNEW
May 1936, British medical journal,
Copied contents to your clipboard!